134 related articles for article (PubMed ID: 19363059)
1. Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
Staessen JA; Richart T; Birkenhäger WH
Eur Heart J; 2009 May; 30(10):1164-6. PubMed ID: 19363059
[No Abstract] [Full Text] [Related]
2. [E-COST].
Kanno Y; Suzuki H
Nihon Rinsho; 2006 Aug; 64 Suppl 6():480-5. PubMed ID: 16981581
[No Abstract] [Full Text] [Related]
3. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan.
Suzuki H; Araki R
Drugs Today (Barc); 2010 Jun; 46(6):427-31. PubMed ID: 20571611
[TBL] [Abstract][Full Text] [Related]
5. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular protection with candesartan in patients with metabolic disorders.
Barrios V; Escobar C; Calderon A
Hypertens Res; 2010 Dec; 33(12):1312-3. PubMed ID: 20664548
[No Abstract] [Full Text] [Related]
8. [CASE-J].
Fukui T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():449-53. PubMed ID: 16981578
[No Abstract] [Full Text] [Related]
9. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).
Kasanuki H; Hagiwara N; Hosoda S; Sumiyoshi T; Honda T; Haze K; Nagashima M; Yamaguchi J; Origasa H; Urashima M; Ogawa H;
Eur Heart J; 2009 May; 30(10):1203-12. PubMed ID: 19346521
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
11. [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Ohya Y; Inoue T
Nihon Rinsho; 2008 Aug; 66(8):1596-600. PubMed ID: 18700563
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Shiga T; Kasanuki H; Hagiwara N; Sumiyoshi T; Honda T; Haze K; Takagi A; Kawana M; Origasa H; Ogawa H;
Blood Press; 2010 Dec; 19(6):359-65. PubMed ID: 20491606
[TBL] [Abstract][Full Text] [Related]
14. [The Heart Institute of Japan--candesartan randomized trial for evaluation in CAD (HUJ-CREATE)].
Hagiwara N; Ogawa H; Kasanuki H
Nihon Rinsho; 2011 Nov; 69 Suppl 9():551-3. PubMed ID: 22724261
[No Abstract] [Full Text] [Related]
15. [Prevention of Cardiovascular Complications in Patients With Arterial Hypertension While Use of Angiotensin II Receptor Antagonists. Possibilities of Candesartan].
Savina NM
Kardiologiia; 2016 Jun; 56(6):63-67. PubMed ID: 28290850
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
17. Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
Almirall J; Valenzuela MP; Lopez T
Nephrol Dial Transplant; 2007 Jan; 22(1):281; author reply 281-2. PubMed ID: 17085461
[No Abstract] [Full Text] [Related]
18. Candesartan: widening indications for this angiotensin II receptor blocker?
Mendis B; Page SR
Expert Opin Pharmacother; 2009 Aug; 10(12):1995-2007. PubMed ID: 19563275
[TBL] [Abstract][Full Text] [Related]
19. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Takahashi A; Takase H; Toriyama T; Sugiura T; Kurita Y; Ueda R; Dohi Y
Nephrol Dial Transplant; 2006 Sep; 21(9):2507-12. PubMed ID: 16766543
[TBL] [Abstract][Full Text] [Related]
20. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
